Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer
Primary Purpose
Diet Modification, Colorectal Adenocarcinoma, Systemic Inflammation
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Very Low Carbohydrate Diet
Sponsored by
About this trial
This is an interventional supportive care trial for Diet Modification focused on measuring Very Low Carbohydrate Diet, Colorectal Adenocarcinoma
Eligibility Criteria
Inclusion Criteria:
- Diagnosed as colorectal adenocarcinoma pathologically
- Decided by a digestive surgery consultant to be managed with best supportive care
- More than 17 years old and capable of making informed consent
- Karnofsky score > 50% or ECOG performance status <=2
- No clinical signs of infection, with one or more of these criteria : fever, leukocytosis, local sign of infection (eg.abscess,ulcer)
- AST < 2 times normal limit
- ALT < 2 times normal limit
- Serum Creatinine < 1,5 times normal limit
- Not pregnant (for women)
- Able to understand and willing participate and to sign informed consent form
- No Diabetes Mellitus
- No fat intolerance
- No severe malnutrition or cancer cachexia
Exclusion Criteria:
- Patient is still on other therapy for the tumour
- Patient with coexisting diseases which prohibits the patient to follow the study protocols
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Very Low Carbohydrate Diet
Control
Arm Description
The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
Outcomes
Primary Outcome Measures
Glasgow Prognostic Score
A score to evaluate systemic inflammation response
Secondary Outcome Measures
Serum Lactate
Lactate level in blood serum
TNF Alpha
Level of Tumor Necrosis Factor Alpha in the blood serum
Full Information
NCT ID
NCT03221920
First Posted
July 16, 2017
Last Updated
July 28, 2017
Sponsor
Dr. Soetomo General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03221920
Brief Title
Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer
Official Title
Effect of Very Low Carbohydrate Diet to Glasgow Prognostic Score, Serum Lactate and TNF Alpha on Colorectal Cancer Patients With Best Supportive Care
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
August 5, 2017 (Anticipated)
Primary Completion Date
August 30, 2017 (Anticipated)
Study Completion Date
August 30, 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Soetomo General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study examine the effects of very low carbohydrate diet (in which the calories requirements are mostly from fat) to the level of systemic inflammation (measured by Glasgow Prognostic Score), serum lactate and TNF Alpha levels
Detailed Description
This study examine the effects of very low carbohydrate diet (in which the calories requirements are mostly from fat) to the level of systemic inflammation (measured by Glasgow Prognostic Score), serum lactate and TNF Alpha levels. The subjects are colorectal adenocarcinoma patients who were decided by experts to be managed by best supportive care. These patients are not deemed to be suitable for surgical intervention , chemotherapy or radiotherapy anymore. The main treatment is supportive. We would like to examined the effect of very low carbohydrate diet on these patients, in which theoretically tumtor cells of the colorectal adenocarcinoma needed glucose to replicate and increases the systemic inflammation response.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diet Modification, Colorectal Adenocarcinoma, Systemic Inflammation, TNF Alpha, Lactate
Keywords
Very Low Carbohydrate Diet, Colorectal Adenocarcinoma
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients were randomized in to two groups, with very low carbohydrate diet and with normal diet
Masking
Care Provider
Masking Description
Care provider are not told whether the patient belongs to intervention or control group
Allocation
Randomized
Enrollment
26 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Very Low Carbohydrate Diet
Arm Type
Experimental
Arm Description
The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
Arm Title
Control
Arm Type
No Intervention
Arm Description
The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
Intervention Type
Other
Intervention Name(s)
Very Low Carbohydrate Diet
Intervention Description
1 : 4 ratio of carbohydrate to fat of the total daily calories intake
Primary Outcome Measure Information:
Title
Glasgow Prognostic Score
Description
A score to evaluate systemic inflammation response
Time Frame
Change of baseline Glasgow Prognostic Score on day 21
Secondary Outcome Measure Information:
Title
Serum Lactate
Description
Lactate level in blood serum
Time Frame
Change of baseline Serum Lactate on day 21
Title
TNF Alpha
Description
Level of Tumor Necrosis Factor Alpha in the blood serum
Time Frame
Change of baseline TNF Alpha serum level on day 21
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed as colorectal adenocarcinoma pathologically
Decided by a digestive surgery consultant to be managed with best supportive care
More than 17 years old and capable of making informed consent
Karnofsky score > 50% or ECOG performance status <=2
No clinical signs of infection, with one or more of these criteria : fever, leukocytosis, local sign of infection (eg.abscess,ulcer)
AST < 2 times normal limit
ALT < 2 times normal limit
Serum Creatinine < 1,5 times normal limit
Not pregnant (for women)
Able to understand and willing participate and to sign informed consent form
No Diabetes Mellitus
No fat intolerance
No severe malnutrition or cancer cachexia
Exclusion Criteria:
Patient is still on other therapy for the tumour
Patient with coexisting diseases which prohibits the patient to follow the study protocols
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vicky S Budipramana, PhD
Phone
0811315812
Email
vickysbudi@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Fransiscus Arifin, MD
Email
farifin@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vicky S Budipramana, PhD
Organizational Affiliation
RS Dr Sutomo
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
18508572
Citation
Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008 May 1;13:5094-107. doi: 10.2741/3066.
Results Reference
background
PubMed Identifier
25460731
Citation
Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, Schoenfeld JD, Buatti JM, Spitz DR, Fath MA. Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biol. 2014;2:963-70. doi: 10.1016/j.redox.2014.08.002. Epub 2014 Aug 7.
Results Reference
background
PubMed Identifier
27557533
Citation
Walenta S, Voelxen NF, Mueller-Klieser W. Lactate-An Integrative Mirror of Cancer Metabolism. Recent Results Cancer Res. 2016;207:23-37. doi: 10.1007/978-3-319-42118-6_2.
Results Reference
background
PubMed Identifier
27993896
Citation
San-Millan I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis. 2017 Feb 1;38(2):119-133. doi: 10.1093/carcin/bgw127.
Results Reference
background
PubMed Identifier
26882261
Citation
Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol. 2016 Mar;17(3):230-40. doi: 10.1038/ni.3384.
Results Reference
background
PubMed Identifier
24343361
Citation
Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014 Mar;35(3):515-27. doi: 10.1093/carcin/bgt480. Epub 2013 Dec 16.
Results Reference
background
PubMed Identifier
22042432
Citation
Venetsanou K, Kaldis V, Kouzanidis N, Papazacharias Ch, Paraskevopoulos J, Baltopoulos G. Measurement of tumour necrosis factor receptors for immune response in colon cancer patients. Clin Exp Med. 2012 Dec;12(4):225-31. doi: 10.1007/s10238-011-0162-5. Epub 2011 Nov 1.
Results Reference
background
Learn more about this trial
Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer
We'll reach out to this number within 24 hrs